CATCH IT EARLY, FIX IT FAST.
Neuright is founded in the belief that relief from the symptoms of peripheral neuropathy is within reach. We envision a world free from peripheral neuropathy by providing better clinical outcomes for the millions suffering from this debilitating condition. We believe that our technology can properly diagnose this condition early, and will be able to deliver treatments when and where they’re needed.
Neuright, Inc. has developed a new theragnostic platform for small fiber peripheral neuropathy in skin and subdermal tissues. Our initial product, a diagnostic called Diagnosing Early Neuropathy (DEN) is a microneedle-based nerve activity monitor that can functionally and quantitatively assess nerve function in healthy tissues, neuropathic tissues, and after treatments or therapies have promoted nerve recovery and regeneration. As a portable, wireless, affordable and easy to use product, a 5- to 10-minute reading can deliver a sensitive diagnostic readout in any clinician’s office without specialized training.
Neuright, Inc. has developed a new theragnostic platform for small fiber peripheral neuropathy in skin and subdermal tissues. Our initial product, a diagnostic called Diagnosing Early Neuropathy (DEN) is a microneedle-based nerve activity monitor that can functionally and quantitatively assess nerve function in healthy tissues, neuropathic tissues, and after treatments or therapies have promoted nerve recovery and regeneration. As a portable, wireless, affordable and easy to use product, a 5- to 10-minute reading can deliver a sensitive diagnostic readout in any clinician’s office without specialized training.
